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Abstract
 
CD4
 
 
 
CD25
 
 
 
 regulatory T cells (T
 
reg
 
) are instrumental in the maintenance of immunological
tolerance. One critical question is whether T
 
reg
 
 can only be generated in the thymus or can
differentiate from peripheral CD4
 
 
 
CD25
 
 
 
 naive T cells. In this paper, we present novel evi-
dence that conversion of naive peripheral CD4
 
 
 
CD25
 
 
 
 T cells into anergic/suppressor cells
that are CD25
 
 
 
, CD45RB
 
 
 
/low
 
 and intracellular CTLA-4
 
 
 
 can be achieved through costimu-
lation with T cell receptors (TCRs) and transforming growth factor 
 
 
 
 (TGF-
 
 
 
). Although
transcription factor 
 
Foxp3
 
 has been shown recently to be associated with the development of
T
 
reg
 
, the physiological inducers for 
 
Foxp3
 
 gene expression remain a mystery. TGF-
 
 
 
 induced
 
Foxp3
 
 gene expression in TCR-challenged CD4
 
 
 
CD25
 
 
 
 naive T cells, which mediated their
transition toward a regulatory T cell phenotype with potent immunosuppressive potential.
These converted anergic/suppressor cells are not only unresponsive to TCR stimulation and
produce neither T helper cell 1 nor T helper cell 2 cytokines but they also express TGF-
 
 
 
 and
inhibit normal T cell proliferation in vitro. More importantly, in an ovalbumin peptide TCR
transgenic adoptive transfer model, TGF-
 
 
 
–converted transgenic CD4
 
 
 
CD25
 
 
 
 suppressor
cells proliferated in response to immunization and inhibited antigen-specific naive CD4
 
 
 
 T
cell expansion in vivo. Finally, in a murine asthma model, coadministration of these TGF-
 
 
 
–
induced suppressor T cells prevented house dust mite–induced allergic pathogenesis in lungs.
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Introduction
 
CD4
 
 
 
CD25
 
 
 
 regulatory T cells (T
 
reg
 
) have emerged as a
unique population of suppressor T cells that maintain periph-
eral immune tolerance (1, 2). Although the immunoregula-
tory ability of T
 
reg
 
 is no longer contested, where and how
this population of CD4
 
 
 
 T cells is generated and developed
still remains largely unknown. The major debate centers on
whether T
 
reg
 
 are generated only in the thymus from a defined
lineage and/or whether these cells represent a stage that
different types of CD4
 
 
 
 T cells can acquire. Although most
analyses emphasize the thymus as the sole incubator for T
 
reg
 
(3, 4), recent evidence suggests that T
 
reg
 
 may also be induced
in the periphery (4, 5). One crucial question is whether
T
 
reg
 
 can be induced or converted from normal peripheral
CD4
 
 
 
 T cells and if this occurs, which molecules and/or
cytokines are responsible for the transition because acti-
vated CD4
 
 
 
 T cells expressing CD25
 
 
 
 under neutral TCR
stimulation conditions show no suppressive ability (1, 2).
TGF-
 
 
 
 is a critical factor in regulation of T cell–mediated
immune responses and in the induction of immune toler-
ance (for reviews see references 6, 7). When the TGF-
 
 
 
1–
mediated inhibitory pathway is abrogated specifically in T
cells by restrictive expression of dominant negative TGF-
 
 
 
receptor II (8, 9), these mice develop unchecked T cell
proliferation and inflammatory and autoimmune-like diseases,
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documenting a TGF-
 
 
 
–dependent signal in T cell activa-
tion and tolerance in vivo. Although TGF-
 
 
 
 regulation of
immune responsiveness has been validated in vitro and in
vivo, how TGF-
 
 
 
 accomplishes its suppressive role in T
cell activation remains unclear. A link between TGF-
 
 
 
 and
induction of T
 
reg
 
 has also been suggested in humans (10),
but whether TGF-
 
 
 
 converts naive T cells to regulatory
cells and, most importantly, the underlying molecular
mechanisms await revelation.
In exciting new papers, 
 
Foxp3
 
, which encodes a tran-
scription factor that is genetically defective in an autoim-
mune syndrome in humans and mice (11, 12), has been
shown to be not only specifically expressed in professional
T
 
reg
 
, but also required for their development (13–15). Nei-
ther naive nor activated CD4
 
 
 
CD25
 
 
 
 responder T cells
express 
 
Foxp3
 
, distinguishing 
 
Foxp3
 
 from other T
 
reg
 
 associ-
ated molecules (CD25, CTLA-4, and GITR) that can be
acquired in CD4
 
 
 
CD25
 
 
 
 responder T cells once activated.
Foxp3/Scurfin-deficient mice develop massive autoim-
mune and inflammatory disease, which shares many patho-
genetic features of mice deficient in CTLA-4 (16, 17) or
TGF-
 
 
 
 (18, 19). Significantly, gene transfer of 
 
Foxp3
 
 con-
verts naive CD4
 
 
 
CD25
 
 
 
 T cells toward a regulatory T cell
phenotype similar to that of the professional T
 
reg
 
 (13–15).
Although the identification of 
 
Foxp3
 
 in T
 
reg
 
 has greatly ex-
panded our ability to decipher the development and func-
tion of this unique population of regulatory T cells, how
 
Foxp3
 
 is controlled and by what physiological inducers re-
main mysteries to be solved.
In this paper, we present evidence that TGF-
 
 
 
 converts
naive CD4
 
 
 
CD25
 
 
 
 T cells into CD4
 
 
 
CD25
 
 
 
 anergic/sup-
pressor T cells in the periphery. These suppressor T cells not
only exhibit unresponsiveness to TCR stimulation, but also
suppress normal CD4
 
 
 
 T cell activation and Th1 and Th2
cytokine production in vitro. Moreover, these suppressor T
cells also inhibit immune responses in vivo, as evident in
their striking prevention of allergic pathogenesis in a house
dust mite (HDM)–induced mouse asthma model and in their
significant suppression of antigen-specific CD4
 
 
 
 T cell pro-
liferation in an OVA peptide CD4
 
 
 
 transgenic T cell adop-
tive transfer model. Significantly, we also show that TGF-
 
 
 
conversion of naive CD4
 
 
 
CD25
 
 
 
 T cells into CD4
 
 
 
CD25
 
 
 
suppressor T cells involves induction of 
 
Foxp3
 
 expression,
the first identification of an inducer of this pathway, which
offers an opportunity to control tolerance.
 
Materials and Methods
 
Mice.
 
Normal BALB/c and DO11.10 transgenic mice ex-
pressing a TCR with specificity for chicken OVA peptide 323-
339 were purchased from The Jackson Laboratory and provided
by B. Kelsall (National Institute of Allergy and Infectious Dis-
eases, Bethesda, MD). C57BL/6 mice were obtained from The
Jackson Laboratory and from in-house breeding at the National
Institute of Dental and Craniofacial Research.
 
Antibodies and Reagents.
 
Crystallized chicken OVA, hen egg
lysozyme, PMA, and ionomycin were purchased from Sigma-
Aldrich. OVA peptide 323-339 (ISQAVHAAHAEINEAGR) was
synthesized and purified by reverse phase–HPLC (Synpep Cor-
poration). The purity of the peptides is 
 
 
 
98%. The following
reagents were obtained from BD Biosciences: purified rat anti–
mouse mAbs to IL-2, IL-4, and IFN-
 
 
 
, anti-CD28, FITC–anti-
CD45RB, recombinant mouse IL-2, IL-4, and IFN-
 
 
 
, PE- or
purified anti-CD3 (145-2C11, NA/LE™), PE-anti–CTLA-4,
hamster IgG isotypic control, FITC- or biotinylated antimurine
CD25 (Clone 7D4), FITC–rat IgM, PE- or purified anti-CD25
(Clone PC61, NA/LE™), and anti-FcRII/III. FITC or PE-anti–
mouse CD4, anti-CD8
 
 
 
, and the respective isotypic control
mAbs and streptavidin-FITC, PE, or Tricolor were purchased
from Caltag. Recombinant human TGF-
 
 
 
1, anti–TGF-
 
 
 
1, 2,3
mAb, biotinylated chicken anti–TGF-
 
 
 
1, and recombinant mu-
rine IL-10 were purchased from R&D Systems. 7-amino-actino-
mycin D (7-AAD) was purchased from Calbiochem.
 
Cell Preparation.
 
Spleens were gently minced in complete
DMEM containing 10% FBS (BioWhittaker), and CD4
 
 
 
 T cells
were purified using a mouse CD4
 
 
 
 T cell column system (R&D
Systems; references 20, 21). T cell–depleted or whole spleen cells
(irradiated, 3,000 rad) of BALB/c or C57BL6 mice were used as
APCs as indicated. To isolate CD4
 
 
 
CD25
 
 
 
 T cells, anti-CD25
antibody (PC61, 1 
 
 
 
g/10
 
6
 
 cells) was added into the antibody
cocktail and incubated with spleen cells before separation on the
CD4
 
 
 
 T cell column, to yield a purity of CD4
 
 
 
CD25
 
 
 
 T cells
 
 
 
90%. For T
 
reg
 
, the CD4
 
 
 
 T cells were incubated with FITC–
anti-CD25 (1 
 
 
 
g/10
 
6
 
 cells; antibody depleted of sodium azide by
dialysis in PBS overnight) in 2% PBS-FBS for 30 min at 4
 
 
 
C,
washed, resuspended in X-Vivo 20 serum-free medium (Bio-
Whittaker), and the T
 
reg
 
 and CD4 CD25  T cells were purified
using a FACStarPlus™ Cell Sorter (Becton Dickinson). The purity
of sorted cells was  95–99%.
Cell Culture and T Cell Proliferation Assay. For normal
C57BL/6 CD4  T cell primary stimulation, purified CD4 ,
CD4 CD25 , or Treg were stimulated with 0.5  g/ml anti-CD3
in the presence of APCs in complete DMEM at 37 C and 5% CO2
for 7–10 d and CD4  T cells were isolated for further studies. In
some studies, 2 ng/ml TGF- 1 was included in the cultures as in-
dicated. In other experiments, CD4 CD25  or CD25  cells were
stimulated with 2  g/ml of platebound anti-CD3 and 2  g/ml
soluble anti-CD28 in the absence or presence of 0.02, 0.2, 2, or 20
ng/ml TGF- 1, 1 ng/ml IL-10, or 100 U/ml IL-2 for 3 d.
For DO11.10 TCR transgenic mice, spleen cells (2   106
cells/ml) were stimulated with 100  g/ml OVA in the absence
or presence of 2 ng/ml recombinant TGF- 1 or 1 ng/ml murine
IL-10 in complete DMEM for 7–10 d. Cells were harvested and
extensively washed, and dead cells were eliminated by centrifuga-
tion over Ficoll-Paque (Amersham Biosciences). For secondary
stimulation, CD4  cells purified from the primary cultures were
restimulated with OVA or anti-CD3 in the presence of APCs as
indicated. For activation with PMA, CD4  T cells were incu-
bated with 5 ng/ml PMA and 250 ng/ml ionomycin. Cells were
cultured at 37 C in 5% CO2 for 72 h and pulsed with 1  Ci
[3H]thymidine for the last 6–16 h. Radioactivity incorporated
was counted using a flatbed   counter (Wallac). In some experi-
ments, 10 U/ml rIL-2 or 20  g/ml anti–TGF- 1, 2,3 mAb and
its isotypic antibody control were added at the beginning of the
secondary culture.
Cytokine Induction and Determination.  For cytokine induc-
tion, cells were cultured with antigens or antibodies as indicated
in complete DMEM for 24–96 h. Cell-free supernatants were
collected for the determination of IL-2, IFN- , IL-4, and IL-13
production by ELISA using paired mAbs specific for the corre-
sponding cytokines (BD Biosciences) or the respective ELISA kitsChen et al. 1877
(Biosource International and R&D Systems). A standard curve
was generated using known amounts of the respective purified
recombinant murine cytokines.
Coculture of CD4  T Cells. Freshly isolated C57BL/6 or
BALB/c CD4 CD25  responder T cells were cultured in
96-well plates with anti-CD3, splenic APCs, and indicated
CD4 CD25  cells for 72 h for proliferation assay. Transwell ex-
periments were performed as described previously (22). In brief,
CD4 CD25  responder T cells were cultured in 24-well plates
with APCs and 0.5  g/ml anti-CD3 in the presence or absence
of TGF- –converted or control CD4 CD25  cells in the Trans-
well™ (0.4  M pore size; Costar). For carboxy-fluorescein diac-
etate succinimidyl ester (CFSE)–labeling assay, 107 cells/ml T
cells were incubated with 3  M CFSE in plain DMEM (without
phenol red) at 37 C for 15 min. Cells were washed three times
and resuspended in complete DMEM for cell culture.
Flow Cytometry Analysis. T cells were resuspended in PBS
containing 1% BSA (Irvine) and 0.1% sodium azide (Sigma-
Aldrich). For the staining of surface antigens, cells were incubated
with FITC-, PE-, or Tricolor-conjugated mAbs or their negative
control antibodies as indicated for 30 min on ice. For surface ac-
tive TGF-  staining, cells were stained with biotinylated chicken
anti–TGF- 1 and FITC–anti-CD25 for 30 min, followed by PE-
streptavidin incubation for an additional 30 min at 4 C. Intracel-
lular staining of CTLA-4 was performed as described previously
(23). Intracellular staining of phosphorylated Smad2/3 (P-Smad2/3)
was performed as described in the figure legend for Fig.
S2 (available  at  http://www.jem.org/cgi/content/full/jem.
20030152/DC1.
Adoptive Transfer Experiments.  Freshly isolated CD4  KJ1-
26  transgenic T cells were injected i.p. into unirradiated synge-
neic BALB/c recipients. Some mice were cotransferred i.p. with
control, TGF- –, or IL-10–pretreated naive CD4  KJ1-26  T
cells. Animals were immunized s.c. with 100  g of P323-339
emulsified in IFA (Difco). Cells from draining lymph nodes (in-
guinal) were harvested at indicated time points and stained ex
vivo with Tricolor–anti-CD4, PE–anti-CD25, and FITC–KJ1-
26 mAbs to determine the expansion of CD4 KJ1-26  T cells in
vivo. For in vitro restimulation assay, draining lymph node cells
were cultured with OVA peptide 323-339 for 3 d to determine
T cell proliferation or for 6 h in the presence of GolgiPlug™
(BD Biosciences) to determine intracellular cytokines as de-
scribed previously (24).
HDM-induced Allergic Pathogenesis.  Allergen-induced asthma
was induced as described previously (25) with some modifica-
tions. In brief, 6–8-wk-old C57BL/6 mice were immunized by
i.p. injection of 10  g HDM antigen (Greer Laboratories) in 0.1
ml PBS or PBS alone (unpublished data) at days 1 and 7, followed
by intratracheal challenge with 100  g HDM antigen in 40  l
PBS or an equivalent volume of PBS as a control at days 14 and
21, respectively. 4 d after the last challenge, mice were killed, and
tissues were harvested for immunohistopathologic analysis or in
vitro cultures. The mucin expression in the airways was deter-
mined with periodic acid schiff (PAS) staining (25). Where indi-
cated, TGF- –anergized or control CD4  T cells were injected
i.v. into the mice on day 1 and again on day 14.
Western Blot Analysis.  Western blot analysis was performed
as described previously (24) with an antibody to P-Smad2/3 (rab-
bit polyclonal IgG, 1:200) or to Smad2/3 (goat polyclonal IgG,
1:200; Santa Cruz Biotechnology, Inc.) followed by horseradish
peroxidase–conjugated goat anti–rabbit IgG or donkey anti–goat
IgG (Santa Cruz Biotechnology, Inc.) as recommended by the
manufacturer.
RT-PCR for Foxp3 Expression.  RT-PCR was performed as
described previously (13), except the number of cycles was 28 for
Foxp3. The primer sequences were as follows and synthesized by
Invitrogen: HPRT, 5 -GTTGGATACAGGCCAGACTTTG-
TTG-3  and 5 -GATTCAACTTGCTCTCATCTTAGGC-3 ;
and  Foxp3, 5 -CAGCTGCCTACAGTGCCCCTAG-3  and 5 -
CATTTGCCAGCAGTGGGTAG-3 . Normalized values for Foxp3
mRNA expression in each sample were calculated as the relative
quantity of Foxp3 divided by the relative quantity of hypoxan-
thineguanine phosphoribosyl transferase (HPRT).
Statistical Analysis. Student’s t tests were used for the signifi-
cance of data comparison.
Online Supplemental Material. Fig. S1 shows that TGF- –
converted CD25+ suppressor cells require cell contact to carry
out their action, and that IL-10–induced CD25+ T cells fail to
suppress normal CD4+ T cell proliferation in vitro. Fig. S2 shows
increased P-Smad2/3 expression in TGF- –converted CD25+
suppressor cells and that anti–TGF-  reverses TGF- –induced
anergy of CD4+ T cells. Fig. S3 shows that cotransfer of TGF- –
converted CD4+ suppressor T cells blocked epithelial cell mucin
production in airways in lungs induced by HDM as detected by
PAS staining. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20030152/DC1.
Results
TCR and TGF-  Costimulation Induces CD4 CD25  T
Cell Anergy, but Fails to Expand Professional Treg. Although
TGF-  suppression of normal CD4  T cell activation has
been validated, it remains unclear whether TGF-  action is
through induction of CD4 CD25  T cell anergy or by pro-
moting growth of existing Treg. First, we studied whether
TCR and TGF-  costimulation could expand a population
of existing Treg in vitro. As expected, freshly isolated Treg
were unresponsive to anti-CD3 stimulation, but could be
coerced to proliferate upon stimulation with anti-CD3 in
the presence of a high dose of exogenous IL-2 (100 U/ml;
references 1, 2; unpublished data). However, after primary
culture with anti-CD3 only or with anti-CD3 and TGF- 
in the presence of APCs for 7 d, most of the Treg died. There
was no increase in the number of Treg in TGF- –treated cul-
tures, but the surviving anti-CD3 plus TGF- –treated Treg,
similar to only anti-CD3–treated cells, remained unrespon-
sive to anti-CD3 restimulation (Fig. 1 A), indicating that ex-
ogenous TGF-  in vitro in the absence of other factors, such
as IL-2, was insufficient to expand the original Treg.
Alternatively, to determine whether TGF-  could aner-
gize CD4 CD25  naive T cells, purified CD4 CD25  T
cells from spleens of normal C57BL/6 (Fig. 1) or BALB/c
(not depicted) mice were cultured with anti-CD3 and APCs
in the presence and absence of TGF-  for 1 wk, harvested,
washed, and restimulated with anti-CD3 and APCs. Consis-
tent with previous papers (1, 2), control CD4  T cells, pre-
cultured with anti-CD3 and APCs (neutral stimulation
condition), proliferated vigorously in response to TCR re-
stimulation (Fig. 1 A). In contrast, anti-CD3 plus TGF- –
pretreated cells were unresponsive to TCR restimulation
(Fig. 1 A) without increased apoptosis (not depicted), consis-
tent with TGF-  induction of CD4 CD25  T cell anergy.TGF-  Induces CD4 CD25  Regulatory T Cells through Induction of Foxp3 1878
Extending this study to CD4  T stimulation with a spe-
cific peptide antigen in TCR transgenic mice, similar results
were obtained. Using TCR transgenic mice DO11.10 in
which the majority of the peripheral CD4  T cells express
clonotypic TCR (KJ1-26 , V  8.2) recognizing the OVA
peptide 323-339, of TGF-  inhibited OVA-specific activa-
tion of these TCR transgenic T cells in primary culture in a
dose-dependent manner (unpublished data). When TGF- 
was included in primary spleen cell cultures with OVA for 1
wk and washed, and the purified transgenic CD4 KJ1-26 
T cells were rechallenged to monitor their secondary re-
sponses, the TGF- –pretreated CD4  T cells exhibited
profound antigen-specific unresponsiveness to OVA or
anti-CD3 in the presence of syngeneic (BALB/c) APCs
(Fig. 1 B), in contrast to the vigorous proliferation of con-
trol cells (Fig. 1 B, OVA   Medium). However, these
TGF- –treated transgenic CD4  T cells proliferated nor-
mally to signals from PMA and ionomycin stimulation (Fig.
1 B). Both OVA-specific production of Th1 (Fig. 1, D and
E, IL-2 and IFN- ) and Th2 (Fig. 1 F, IL-4) cytokines were
blunted in TGF- –pretreated transgenic CD4  T cells.
This antigen-specific T cell unresponsiveness was not due to
cell death because TGF- –treated transgenic T cells mani-
fested similar numbers of apoptotic cells compared with
control as determined by DNA dye 7-AAD (20, 21) after
16-h restimulation with OVA and APCs (7-AAD  OVA  
Medium [13%] vs. OVA   TGF-  [17%]). These data sug-
gest that TGF- 1 induces both antigen-specific Th1 and
Th2 cell anergy in transgenic CD4  T cells.
Because exogenous IL-2 reportedly blocks T cell anergy
(26), we included IL-2 in secondary restimulation cultures
and found that it reversed the antigen-specific suppression
of T cell proliferation (Fig. 1 B) and Th1 and Th2 cytokine
production in TGF- –anergized T cells (Fig. 1, D–F). To
study IL-2 effects on the induction phase of the TGF- –
induced anergy, IL-2 was included in the primary culture
with OVA plus TGF-  for 7 d, and cells were washed and
restimulated with OVA or anti-CD3 in the absence of IL-2.
Under these conditions, TGF- –induced suppression of
TCR-specific T cell proliferation was abrogated (Fig. 1 C),
documenting that IL-2 not only reverses TGF- –induced
anergy, but also abolishes the development of TGF- –
induced CD4  T cell anergy. Thus, in two discrete sys-
tems, TGF-  was uniquely able to induce CD4 CD25 
cells into an anergic state.
TCR and TGF-  Converts CD4 CD25  T Cells to
CD4 CD25  Suppressor T Cells In Vitro. We studied
whether the TGF- –anergized CD4  T cells were func-
tionally active and able to suppress responder T cell prolif-
eration. Freshly isolated CD4 CD25  naive T cells were
cultured with anti-CD3 and APCs in the absence and
presence of TGF- . After 1 wk, viable CD4  T cells
were stained with FITC–anti-CD25 and sorted with flow
cytometry into four populations (Fig. 2 A): Control
CD4 CD25  (control 25 ) and CD4 CD25  (control
25 ), and TGF- –treated CD4 CD25  (TGF-  25 ) and
CD4 CD25  (TGF-   25 ). The individual populations
were restimulated with anti-CD3 and APCs (Fig. 2 B).
Both control 25  (3H uptake mean CPM   35,661) and
control 25  (mean CPM   65,057) cells proliferated vig-
orously (Fig. 2 B). In contrast, TGF-  25  exhibited re-
duced TCR-triggered proliferation (mean CPM   14,684)
as did TGF-  25  cells (Fig. 2 B, mean CPM   2,471).
Most importantly, when these individual populations were
Figure 1. Costimulation of TCR and
TGF-  induces CD4 CD25  T cell anergy,
but fails to expand existing Treg. (A)
C57BL/6 CD25  naive cells or Treg (5  
104) were cultured (primary) with anti-CD3
and APCs (2   106) in the absence ( CD3  
med) and presence ( CD3   TGF- ) of
2 ng/ml TGF-  for 7 d. 3   104 harvested
viable CD4  responder T cells or 5   103
Treg were restimulated with anti-CD3 and
APCs for 72 h to monitor their prolifera-
tion. The data are representative of three
separate experiments. (B–F) TGF-  induces
OVA TCR transgenic CD4  T cells (KJ1-
26 ) anergy. 2   106 cells/ml spleen cells
were cultured with OVA in the presence or
absence of TGF-  for 7–10 d (primary).
Viable CD4  T cells were purified and re-
stimulated with 100  g/ml OVA, 100  g/ml
hen egg lysozyme (HEL), 1  g/ml anti-
CD3 mAb, or 10 U/ml IL-2 as indicated in
the presence of BALB/c APCs or with
PMA and ionomycin (secondary stimulation).
The values are expressed as mean   SD of
triplicate wells for 3H incorporation (CPM,
5   104 T cells) (B and C) or of duplicate
wells of the ELISA (D–F, 2   104 T cells).
(B) TGF-  induces transgenic CD4  TCR-specific anergy. (C) Inclusion of exogenous IL-2 in primary cultures blocks TGF- –induced CD4  T cell
anergy. (D–F) TGF-  induces both Th1 and Th2 cell anergy. Cytokine levels of IL-2 (D), IFN-  (E), and IL-4 (F) in secondary culture supernatants
(after 24–48 h) were determined by ELISA. The data shown were repeated from two to six times with similar results.Chen et al. 1879
cocultured with freshly isolated CD4 CD25  naive re-
sponder T cells, only the TGF-  25  cells inhibited the
anti-CD3–induced responder T cell proliferation (Fig. 2 C;
Fig. S1 H, available at http://www.jem.org/cgi/content/
full/jem.20030152/DC1). Neither control 25  nor control
25  had any suppressive action (Fig. 2 C; Fig. S1 H). Inter-
estingly, TGF- –treated cells that remained 25  cells also
lacked suppressive action to normal T cell proliferation, de-
spite their anergy to TCR stimulation (Fig. 2 B). Similar
results were obtained in normal BALB/C mice (unpub-
lished data). When CD4 CD25  responder T cells were
labeled with CFSE and cocultured with TGF-  25  or
control 25  T cells, only TGF-  25 , but not control 25 
T cells, blocked CFSE-labeled reduction as a marker of
proliferation in CD25  responder cells (Fig. S1, A–D). The
immunosuppressive action in vitro was dependent on cell
contact because no inhibition occurred when TGF- –con-
verted suppressor T cells were separated from the responder
cells in Transwell™ plates (Fig. S1, E and F). If TGF-  was
replaced with IL-10, another potent immunoregulatory cy-
tokine, in parallel cultures of naive CD4 CD25  T cells
for 7 d, the resultant CD4 CD25  T cells (IL-10 25 ) ex-
hibited no suppression to normal CD4  T cell proliferation
in vitro (Fig. S1, G and H). The data support a role for
TGF-  in the conversion of CD4 CD25  naive/re-
sponder into CD4 CD25  anergic/suppressor T cells.
Phenotype of TGF- –induced Anergic/Suppressor CD4  T
Cells. We determined whether TGF- –induced anergic/
suppressor T cells exhibited a phenotype comparable to
that of Treg (e.g., CD25 , CD45RB /low) and intracellular
CTLA-4 (1, 23). OVA TCR transgenic CD4  T cells
were stimulated with OVA in the presence or absence of
TGF- . After 1 wk, TGF- –anergized viable CD4  trans-
genic T cells were found to be smaller in size (Fig. 3 A), to
express CD25  (Fig. 3 B), and to show reduced CD45RB
(Fig. 3 C, CD45RB /low).
Next, we focused on the expression of CTLA-4 associ-
ated with Treg (23, 27, 28). After primary culture for 7 d,
viable transgenic CD4  T cells were isolated and main-
tained in complete DMEM for up to 56 h without addition
of any growth factors or cytokines to rest the T cells com-
pletely. The CD4  T cells were doubly stained with anti–
CTLA-4 antibody together with KJ1-26, and both surface
and intracellular CTLA-4 levels were examined. Although
almost all surviving control CD4  transgenic T cells lost
their intracellular (8%) and surface (1.5%) CTLA-4 as typi-
cal resting T cells (Fig. 3 D), TGF- –anergized CD4 
KJ1-26  T cells retained intracellular CTLA-4  (56%), al-
beit not on the surface (2.2%; Fig. 3 D and not depicted).
Similar results were obtained when normal B6 and BALB/c
CD4  T cells were cultured with anti-CD3 plus TGF- 
(unpublished data). Thus, TGF- –induced anergic/sup-
pressor CD4  T cells exhibit a similar phenotype to Treg.
TGF- –induced Anergic/Suppressor CD4  T Cells Express
Cell Membrane–bound Active TGF- . Previous papers have
shown that the Treg express cell membrane–bound TGF- ,
which is involved in Treg cell contact–dependent immuno-
suppression (references 29, 30; unpublished data). We ex-
amined whether TGF- –induced anergic/suppressor T
cells express increased TGF- . Naive C57BL/6 CD4 
CD25  T cells were stimulated with anti-CD3 and APCs
in the presence or absence of TGF-  for 3 d, washed
extensively, and stained doubly with antibody to active
TGF-  and anti-CD25. As expected, most of the CD4  T
cells ( 90%) expressed CD25 after TCR stimulation for 3 d.
The striking finding was that the majority of TGF- –
treated CD25  T cells ( 50–80%) exhibited cell surface ac-
tive TGF- , whereas only a few CD25  T cells ( 3–5%) in
control cultures (anti-CD3 alone) were positive for surface
TGF- , determined by flow cytometry (Fig. 3 E) and im-
munofluorescence microscopy (Fig. 3 F). To establish a link
between their increased surface TGF-  and functional an-
ergy to TCR stimulation, anti-CD3 restimulation showed
increased phosphorylation of Smad2/3, which are key me-
Figure 2. TGF-  converts naive CD4 CD25  T cells to CD4 
CD25  anergic/suppressor T cells. (A) Schematic for the experi-
ment. Freshly isolated B6 CD4 CD25  T cells were stimulated with
anti-CD3 and APCs in the absence and presence of TGF-  for 1 wk.
Viable CD4  T cells were stained with FITC–anti-CD25 mAb, and four
populations of cells (control 25 , control 25 , TGF-  25 , and TGF- 
25 ) were sorted by FACStarPlus™ Cell Sorter. (B) The individual popu-
lations (5   104) were restimulated with anti-CD3 and APCs (2   105)
to monitor their proliferative response. The data are shown as mean of
duplicate wells of 3H incorporation (CPM). (C) 1.5   104 freshly iso-
lated CD4 CD25  responder T cells were stimulated with anti-CD3
and APCs in the absence (naive CD25  alone) or presence of the four
individual populations of cells (5   104) to examine their suppressive
ability for naive responder T cell activation. The data are representative
of three experiments.TGF-  Induces CD4 CD25  Regulatory T Cells through Induction of Foxp3 1880
diators of TGF-  signaling (6, 7) and which is indicative of
TGF-  signal transduction, by Western blot analysis (Fig.
S2 A) or intracellular immunofluorescence staining (Fig. S2
B). Furthermore, when anti–TGF-  neutralizing monoclo-
nal antibody was included in secondary restimulation cul-
tures of these anergic T cells, anti–TGF- , but not isotypic
control antibodies, reversed their proliferation (Fig. S2 C),
as well as IL-2, IFN- , and IL-4 production (not depicted).
Anti–TGF-  had no apparent effects on control CD4  T
cells (Fig. S2 C, OVA   Med), consistent with their lack of
surface TGF-  (Fig. 3, E and F). Thus, TGF- –induced
anergic/suppressor CD4  T cells expressed increased TGF- ,
which likely mediates their own anergic state, as well as
their suppression of normal T cell activation.
TGF-  Induces Foxp3 Expression in CD4 CD25  Naive/
Responder T Cells. Although TGF-  converts peripheral
naive CD4 CD25  T cells into anergic/suppressor T cells,
the molecular mechanisms by which TGF-  drives this
transition are unknown. Transcription factor Foxp3 is a re-
cently described gene associated with the development of
regulatory T cells, and retroviral gene transfer of Foxp3 into
naive responder T cells converts them toward a regulatory
T cell phenotype (13–15). The physiological inducers for
Foxp3 gene expression remain a mystery, but we reasoned
whether TGF-  might trigger Foxp3 expression in CD4 
CD25  naive/responder T cells, switching them toward a
regulatory phenotype.
Freshly purified ( 99%) Treg(CD25 ), but not CD4 
CD25  (CD25 ) naive responder T cells, in normal
C57BL/6 mice express Foxp3 (Fig. 4 A; references 13–15).
When naive responder T cells were stimulated with anti-
CD3 and anti-CD28, the Foxp3 gene was not up-regulated
(Fig. 4 B), consistent with previous findings (13–15). Signif-
icantly, stimulation of naive responder T cells with anti-
CD3 and anti-CD28 (Fig. 4 B) or with anti-CD3 and APCs
(Fig. 4 C) in the presence of active TGF-  dramatically in-
duced Foxp3 expression, which was dependent on the levels
of TGF-  (Fig. 4 D), whereas TGF-  treatment alone
failed to elicit Foxp3 (Fig. 4 B). Similar results were ob-
served in BALB/c mice (unpublished data), indicating a
generality of the effect. By comparison, stimulation of
Foxp3-expressing Treg with anti-CD3 and anti-CD28 and a
high dose of IL-2 (100 U/ml), a regimen for their prolifera-
tion (1), did not increase constitutive Foxp3 (Fig. 4 E; refer-
ence 13), nor did the addition of TGF-  (Fig. 4 E). Separa-
tion of TGF-  and anti-CD3–cultured CD4 CD25  cells
(day 7) into CD25  suppressor and CD25  nonsuppressor
cells by FACS® (Fig. 2 A and Fig. 4 F) revealed that the
TGF- –converted CD25  subset had much higher levels of
Foxp3 than did the CD25  subpopulation (Fig. 4 G). As ex-
Figure 3. Phenotype of TGF-
 –induced anergic/suppressor T
cells. (A–D) DO11.10 TCR
transgenic spleen cells were stim-
ulated with OVA in the absence
(OVA   Med) and presence of
TGF-  (OVA   TGF- ) for
7 d. CD4  T cells were purified
and stained with PE–anti-CD4
and FITC–anti-CD25, or FITC–
anti-CD45RB. CD4  T cells
( 98% KJ1-26 ) were gated,
and histogram profiles of cell size
on FSC (A) and CD25 (B) are
displayed. Profile of dual CD4
and CD45RB expression (C)
CD4  T cells purified at day 7
after the primary cultures were
rested in complete DMEM for
56 h. Viable CD4  T cells were
stained with FITC-anti–KJ1-26
and intracellular PE-anti–
CTLA-4. (D) TGF- –induced
anergic/suppressor T cells express
membrane-bound TGF-   (E
and F). B6 CD4 CD25  T cells
were cultured with anti-CD3
and APCs in the absence (panels
a and b,  CD3   Med) or pres-
ence of TGF-  (panels c and d,
 CD3   TGF- ) for 3 d. After
extensive washes, cells were
stained with FITC–anti-CD25
and biotinylated chicken anti–
TGF- 1, followed by streptavi-
din-PE. Cells were analyzed on
flow cytometry and under im-
munofluorescence microscopy.Chen et al. 1881
pected, both CD25  and CD25  subsets from control cul-
tures had undetectable Foxp3 (Fig. 4 H). On the other
hand, IL-10 failed to induce Foxp3 expression in naive
CD4 CD25  cells (Fig. 4 D) or to further enhance Foxp3
in Treg (Fig. 4 E). Thus, costimulation of Foxp3-negative
CD4 CD25  naive responder T cells with TCR engage-
ment in the presence of TGF-  induces de novo expression
of Foxp3, concomitant with conversion to a population of
CD4 CD25  Foxp3  T cells phenotypically and function-
ally indistinguishable from professional Treg.
TGF- –induced CD4  Transgenic Anergic/Suppressor T
Cells Suppress OVA-specific T Cell Proliferation In Vivo.
Extending these studies in vivo, first we used an adoptive
transfer model (31, 32) in which transgenic CD4  KJ1-
26  T cells were transferred into syngeneic BALB/c mice
followed by OVA peptide immunization. The prolifera-
tion of the transgenic CD4  T cells in host mice was
monitored using clonotypic antibody KJ1-26 (Fig. 5). In
contrast to their anergic state in vitro, the TGF- –con-
verted CD4 CD25  transgenic suppressor T cells (TGF- 
Cell) expanded at similar levels as control CD4  trans-
genic T cells (Control Cell) in vivo after OVA peptide
323-339 immunization (Fig. 5 E and not depicted; with-
out immunization, recovered CD4 KJ1-26  T cells were
 0.1   105 in draining lymph nodes in all groups). Signif-
icantly, the recovered CD4  KJ1-26  T cells from drain-
ing lymph nodes receiving TGF-  Cell expressed high
levels of CD25 ( 70%) and preserved their specific unre-
sponsiveness to OVA peptide 323-339 restimulation in
vitro (unpublished data). CD4 KJ1-26  T cells recovered
from mice receiving Control Cell had much lower levels
of CD25 (28%) and proliferated vigorously to OVA pep-
tide 323-339 (unpublished data). When cotransferred with
naive/responder CD4  transgenic T cells, the TGF- 
Cell, but not Control Cell, blocked antigen-specific ex-
pansion of naive CD4 KJ1-26  T cells in draining lymph
nodes (Fig. 5, A–C and E). Importantly, the recovered
CD4 KJ1-26  T cells from the mice injected with naive
CD4 KJ1-26  cells plus TGF-  Cell also expressed much
higher levels of CD25 (Fig. 5 c) compared with that in
mice injected with naive CD4  T cells alone (Fig. 5 a) or
plus Control Cell (Fig. 5 b). Interestingly, in contrast to
their nonsuppressive features in vitro, IL-10–induced
CD4  transgenic T cells (IL-10 Cell) suppressed antigen-
driven CD4 KJ1-26  T cell proliferation in vivo (Fig. 5,
D and E). However, the recovered CD4 KJ1-26  T cells
from mice receiving IL-10 cells expressed reduced CD25
(Fig. 5 d) compared with those from mice receiving TGF- 
Cell (Fig. 5 c).
When draining lymph node cells were restimulated in
vitro with OVA peptide 323-339, the antigen-specific T
cell proliferation from mice cotransferred with TGF- 
Cell was significantly inhibited compared with that of
mice receiving naive CD4 KJ1-26  T cells alone (Fig. 5
Figure 4. TGF-  and TCR
costimulation induces Foxp3
expression in CD4 CD25 
naive responder T cells. (A) B6
spleen cells were sorted into
CD4 CD25  (CD25 ) and Treg
(CD25 ) populations. cDNA
from each population was sub-
jected to nonsaturating PCR
using  Foxp3 or HPRT-specific
primers, and data are presented as
Foxp3/HPRT ratio. (B) CD25 
cells were cultured with medium
or 2 ng/ml TGF- 1 (24 h) or
stimulated with platebound anti-
CD3 and soluble anti-CD28 in
the absence or presence of TGF-
 1 (72 h) and assessed for the
expression of Foxp3 by RT-PCR.
(C) CD25  cells were activated
with soluble anti-CD3 and
APCs with or without TGF- 
for 3 d and assessed for Foxp3
expression. (D) Dose depen-
dence of TGF-  and failure of
IL-10 on Foxp3 induction in
CD25  naive T cells. CD25 
cells were cultured as in B in the
presence of indicated concentra-
tions of TGF-  or recombinant
murine IL-10. (E) Both TGF- 
and IL-10 failed to further enhance Foxp3 expression in Treg. Freshly isolated Treg were activated with platebound anti-CD3, soluble anti-CD28, and IL-2
(100 U/ml) with or without TGF-  or IL-10, and Foxp3 expression was assessed by RT-PCR. (F and G) Flow cytometry analysis (F) and Foxp3 expression
(G) of CD25  or CD25  T cells sorted from TGF- – and anti-CD3–costimulated naive CD25  T cells (day 7). (H) No Foxp3 expression in both
CD25  and CD25  subsets purified from control (anti-CD3 only) stimulated CD25  naive cells (day 7). The data in the figure are representative of at
least three experiments.TGF-  Induces CD4 CD25  Regulatory T Cells through Induction of Foxp3 1882
F). The antigen-specific IL-4 and IFN-  production in
recovered CD4 KJ1-26  T cells was also inhibited in
mice cotransferred with TGF-  suppressor cells (Fig. 5
G). The recovered CD4 KJ1-26  T cells from mice
cotransferred with IL-10 Cell exhibited less inhibition of
OVA-specific T cell proliferation and cytokine produc-
tion (Fig. 5, F and G). Clearly, TGF- –converted CD25 
T cells have regulatory ability for antigen-induced naive
CD4  T cell activation in vivo, consistent with the func-
tional features of Treg (31, 32), but distinct from IL-10–
induced CD25  T cells.
TGF- –induced CD4  Anergic/Suppressor T Cells Prevent
HDM-induced Allergic Pathogenesis In Vivo. The immuno-
regulatory effect of TGF- –induced anergic/suppressor
CD4  T cells in vivo was further assessed in an antigen-
induced allergic model. C57BL/6 CD4 CD25  naive T
cells were cultured with anti-CD3 and APCs in the ab-
sence or presence of TGF-  for 3–4 d, washed extensively,
and rested in complete medium containing IL-2 for an ad-
ditional 3 d. Viable cells were harvested and delivered in-
travenously into mice immunized and challenged with
HDM as depicted in Fig. 6 A. After HDM intraperitoneal
immunization and intratracheal challenge, massive inflam-
matory cell infiltrates were evident with mucus obstruction
of the airway in the lung (Fig. 6 C), compared with the
lung tissues in naive or PBS-injected mice (Fig. 6 B and
not depicted). Administration of control CD4  T cells
(Control Cell) pretreated with anti-CD3 alone failed to re-
duce the inflammatory cell infiltration significantly, al-
though mucus was less obvious in the airways (Fig. 6 D). In
contrast, administration of TGF- –converted CD4  sup-
pressor T cells (TGF-  cell) dramatically reduced HDM-
induced inflammatory cell infiltration and preserved the
integrity of airway structures (Fig. 6 E). Cotransfer of
Figure 5. TGF- –converted CD4  sup-
pressor T cells inhibited antigen-specific
expansion of transgenic CD4  T cells in
vivo. Freshly isolated CD4  KJ1-26  T cells
(DO11.10 CD4  cells) or with equal number
of OVA only (Control cell), plus 2 ng/ml
TGF-  (TGF-  cell) or plus 1 ng/ml IL-10–
converted (IL-10 cell) CD25  KJ1-26  T
cells were injected i.p into normal BALB/c
mice. Some mice were injected with 2.5  
105 of Control cell, TGF-  cell, or IL-10
cell alone. Mice were immunized with
Peptide 323-339 emulsified with IFA on
day 2. On day 11, draining lymph nodes
(inguinal) were harvested, and cells were
stained with Tricolor–anti-CD4, FITC–
KJ1-26, and PE–anti-CD25 and analyzed
on FACSCalibur™. (A–D) Live cells were
gated, and the profiles between CD4 versus
KJ1-26 are displayed. The numbers repre-
sent CD4 KJ1-26  cell frequency within
lymph node cells. The numbers in the paren-
theses  are injected cells. Each group con-
tained two mice and the lymph node cells
were pooled before staining. (a–d) CD4 KJ1-
26  T cells in corresponding A–D were
gated, and CD25  frequency is shown. (E)
Total CD4 KJ1-26  T cells in draining
lymph nodes per mouse (percentage of
CD4 KJ1-26     the number of total
lymph node cells/2). (F) 2   106 lymph
node cells labeled with 3  M CFSE were
cultured with 1  g/ml Peptide 323-339 in
24-well plates for 72 h. Cells were stained
with Tricolor–anti-CD4 and PE–KJ1-26
and analyzed on FACSCalibur™. CD4 KJ1-
26  cells were gated, and the CFSEhi cells
are shown. The marker was set according to
CFSE fluorescence of the live CD4  KJ1-
26  T cells in parallel cultures with medium
only. (G) 2   106 lymph node cells were
cultured with Peptide 323-339 in the presence
of GolgiPlug™ for 5–6 h. Cells were
stained with Tricolor–anti-CD4 and FITC–
KJ1-26 antibodies before being fixed and
intracellularly stained for IL-4 or IFN-  cytokines with respective antibodies (PE-anti–IL-4 or PE-anti–IFN- , 0.5  g/106 cells). 40,000–80,000 cells
were acquired on FACSCalibur™, and percentages of KJ1-26  IL-4  or IFN-   cells within CD4  T cells are shown. The experiments were repeated
twice with similar results.Chen et al. 1883
TGF- –converted CD4  suppressor T cells blocked epi-
thelial cell mucin production in airways induced by HDM
as detected by PAS staining, whereas control CD4  T cells
did not (Fig. 6, B–E; Fig. S3, available at http://www.
jem.org/cgi/content/full/jem.20030152/DC1). Spleen T
cells from mice treated with HDM and TGF- –induced
anergic/suppressor CD4  T cells produced much lower
levels of HDM-specific, as well as anti-CD3 driven, Th1
(IFN- ) and Th2 (IL-4 and IL-13) cytokines compared
with mice receiving HDM alone (Fig. 6, F–H). In contrast,
spleen T cells from mice treated with HDM and control
CD4  T cells produced higher levels of IFN-  (Fig. 6 F),
although these cells produced reduced levels of IL-4 and
IL-13 (Fig. 6, G and H). Thus, TGF- –induced anergic/
suppressor CD4  T cells dampen inflammation and associ-
ated mucin production in allergic immune responses in
vivo.
Discussion
Of many unresolved questions regarding Treg, where and
how they are generated remains significant (2, 33). In this re-
port, we have provided evidence that Treg can be induced/
converted from peripheral CD4 CD25  naive responder T
cells through costimulation of TCR and TGF-  signaling.
Several important conclusions can be drawn from the current
work. First, TGF-  treatment in the presence of TCR stim-
ulation converts naive CD4 CD25  responder T cells to an-
ergized CD4 CD25  T cells, but fails to promote growth of
existing Treg, at least in vitro. The effect of TGF-  on the fate
of T cell activation is determined not only by TGF-  con-
centration, but also by the level of IL-2. Importantly, exoge-
nous IL-2 not only reverses unresponsiveness to TCR restim-
ulation of TGF- –anergized CD4  T cells but also
antagonizes the induction of CD4  T cell anergy by TGF- .
Second, TGF- 1–converted anergic CD4  T cells are
Figure 6. TGF- –converted-CD4  sup-
pressor T cells prevent HDM-induced allergic
pathogenesis in vivo. B6 CD4 CD25  T
cells were cultured with anti-CD3 and
APCs in the absence (Control cell) and
presence of TGF-  (TGF-  cell) for 3–5 d,
extensively washed and rested in DMEM
complete medium containing 10 U/ml of
IL-2 for an additional 3 d. Viable cells were
harvested, washed, and resuspended in PBS
for injection. For induction of allergic
immune responses in lungs, B6 mice were
injected with HDM allergen as depicted in
schematic plan (A). 4 d after the last HDM
intratracheal challenge, mice were killed,
and lungs were immediately fixed with 10%
PBS-Formalin for immunohistological
staining (H&E). One representative lung
from each group (three to five mice) is
shown. The magnification of the images is
20. (B) Naive lung. (C) HDM-injected
lung. (D) HDM-injected lung coinjected
with Control cell (106 on day 1 and 5   105
on day 14, i.v.). (E) HDM-injected lungs
coinjected with TGF-  cell (106 on day 1
and 5   105 on day 14, i.v.). (inset) Boxed
images are mucin staining in airways by
PAS (40 ). The red staining represents
mucin positive cells. (F–H) Spleen cells
were harvested and pooled from three to
five mice per group. 4   105 spleen cells
were cultured with 100  g/ml HDM
(white bars) or 0.5  g/ml anti-CD3 (black
bars) for 24–96 h, the cell-free supernatants
were collected to measure IFN-  (F, 48 h),
IL-4 (G, 24 h), and IL-13 (H, 96 h), respec-
tively, by ELISA. IL-4 levels are shown as
 OD (OD value of test supernatants   OD
value of culture medium; OD    0.107).
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suppressor cells. Phenotypically, TGF- –converted aner-
gic/suppressor T cells retain surface CD25  and exhibit
CD45RB /low, similar to professional Treg (2, 34). Another
key finding is that TGF- –anergized CD4 CD25  T cells
express intracellular CTLA-4 as do Treg (23, 27, 28). TGF- 
regulation of intracellular CTLA-4 in CD4  T cells does
not appear to involve induction of CTLA-4 synthesis, but
rather prevention of its degradation (unpublished data).
Functionally, when cocultured with normal CD4  T cells,
TGF- 1–anergized T cells inhibit proliferation and cyto-
kine production of the target T cells. This suppressive ac-
tivity is mainly attributed to the CD25  subpopulation of
anergized cells, because TGF- –anergized cells lacking
CD25, at least in vitro, have no obvious suppressive ability.
Neither CD25  nor CD25  T cells from control cultures
(without TGF- ) have suppressive activity, consistent with
previous observations (1, 2, 34, 35). The level of immuno-
suppression is dependent on the cell number and reversible
by exogenous IL-2. Consistent with Treg, TGF- –con-
verted CD25  suppressor T cells also require cell contact to
carry out their suppression, which can be mediated by cell
membrane–bound TGF-  (29, 30).
The data that TGF- –converted CD4 CD25  T cells
express cell surface TGF-  in active form provide further
evidence that the professional Treg can be converted by
TGF-  and TCR costimulation from peripheral naive
CD4  T cells. Although not unanimous, increasing evi-
dence has demonstrated that Treg produce/express higher
levels of TGF- , which plays a significant role in immune
regulation in vitro and in vivo (27, 29, 30, 36, 37). That
TGF- –converted CD25  suppressor T cells express cell
surface TGF-  not only supports the concept that these
suppressor cells possess the same phenotype as the profes-
sional Treg but also offers an explanation for how profes-
sional Treg are developed. Although how these TGF-  sup-
pressor T cells acquire surface TGF-  remains elusive, it is
conceivable that TGF-  enhances its own production as
evident by exogenous TGF-  up-regulation of its own
mRNA expression in CD4  T cells (reference 7; unpub-
lished data) and/or TGF-  binds onto its cognate receptors
on these suppressor T cells, because TCR stimulation en-
hances TGF-  receptor expression in CD4  T cells (un-
published data). The cell membrane–bound TGF-  is
likely involved in unresponsiveness to TCR engagement
and suppression of normal T cells by these TGF-  anergic/
suppressor T cells because restimulation of the suppressor
cells drives a higher level of phosphorylation of Smad2/3,
and anti–TGF-  antibody reverses their anergy and abro-
gates their suppressive action.
The strongest evidence that TGF-  converts CD4 
CD25  naive T cells to CD25  regulatory cells
comes from our surprising findings that TGF-  and TCR
costimulation induces transcription factor Foxp3 gene ex-
pression in CD4 CD25  T cells. The observation that
TGF-  induces Foxp3 expression in CD4 CD25  naive T
cells has led to several unprecedented conclusions. First,
TGF-  can induce Foxp3 expression in CD4  CD25  T
cells under conditions involving either anti-CD3 and anti-
CD28 costimulation in the absence of APCs or with anti-
CD3 in the presence of APCs, suggesting the dispensability
of APCs. The Foxp3 induction is dependent on the levels
of TGF- , suggesting the causal influence of TGF- . Sec-
ond, in the absence of TCR stimulation, TGF-  itself fails
to induce or enhance Foxp3 expression, indicating the ne-
cessity of TCR engagement. Moreover, when CD25  and
CD25  subsets were isolated from TGF- – and TCR-
costimulated cultures, CD25  T cells exhibited much higher
levels of Foxp3 than the CD25  subset, supporting the no-
tion that Foxp3 may be involved in Treg immunoregulation
(38). Lastly, TGF-  had no further enhancement on exist-
ing Foxp3 gene in professional Treg, consistent with the ev-
idence that Foxp3 expression is stable in Treg (13). The fail-
ure of IL-10 to induce Foxp3 in CD25  naive T cells
indicates that IL-10 is not a physiological inducer for Foxp3
expression. Although mechanistically elusive, the observa-
tion that IL-10–induced CD25  T cells lack characteristic
suppression in vitro, but are functional in vivo suggests that
these cells are distinct from TGF- –converted CD25  reg-
ulatory cells. The data are consistent with the notion that
IL-10 is more likely a switch for CD4  T cells into Trl cells
(39). These discriminating results not only provide a mo-
lecular mechanism for the TGF- –driven transition of na-
ive T cells toward regulatory T cells, but also unveil the
first physiological inducer for Foxp3 expression in CD4 
naive/responder T cells, which may enable manipulation of
this specific population of regulatory cells.
More importantly, these TGF- 1–converted CD4 
CD25  suppressor cells also inhibit T cell responses
when transferred in vivo. Evidence from the OVA trans-
genic adoptive transfer model document that TGF- –con-
verted CD25  suppressor cells resemble Treg. First, TGF-
 –converted CD25  suppressor T cells proliferate in vivo
upon specific antigen immunization, yet preserve their an-
tigen specific anergy when recultured in vitro. Second,
transgenic CD4 KJ1-26  T cells recovered from mice re-
ceiving TGF- –converted suppressor cells expressed ele-
vated CD25. Significantly, TGF- –converted KJ1-26 
CD25  suppressor cells inhibit antigen-driven CD4  T cell
growth in vivo. Again, the recovered CD4 KJ1-26  cells
from the suppressed draining lymph nodes show high levels
of CD25 and fail to respond to specific antigen stimulation.
All these phenotypic and functional features of TGF- –
converted suppressor T cells are consistent with those of
professional Treg (31, 32). Moreover, TGF- –converted
suppressor T cells may carry out their suppression in vivo
in a nonspecific manner because TGF- –converted
BALB/c CD25  T cells harvested from the primary cul-
tures exhibit the inhibition of antigen-driven expansion of
the transferred CD4 KJ1-26  T cells (unpublished data).
In HDM-induced allergic immune responses in lungs,
TGF- –converted suppressor T cells ameliorate allergen-
driven inflammatory cell infiltration and mucin production
in airways. Anergic/suppressor T cells appear to inhibit
both Th1 and Th2 responses, whereas administration ofChen et al. 1885
control CD4  cells enhanced Th1 IFN- , which might
contribute to the inhibition of Th2 cytokines, but failed to
significantly limit the inflammatory response in the lungs,
indicating the complexity of the Th1 effector T cell role in
allergic lung inflammation (40). Interestingly, we also ob-
served an increase in TGF-  production in the TGF- 
suppressor cell–treated mice (unpublished data), which re-
flects previous findings that the professional Treg require
TGF-  in vivo to carry out their suppressive activity (27),
and supports our evidence that TGF-  and TCR costimu-
lation convert naive CD4  T cells toward a regulatory T
cell phenotype mimicking professional Treg.
In summary, we have provided evidence for TGF- 1 as
a critical factor in the development of peripheral Treg. The
present paper has not only demonstrated that TGF-  con-
verts CD4 CD25  naive T cells toward a suppressor T cell
phenotype similar to that of Treg but also uncovered that
TGF-  induces transcription factor Foxp3 expression in
CD25  naive T cells to enforce transition to regulatory T
cells. Functionally, TGF- –converted suppressor T cells
not only suppress T cell proliferation and Th1 and Th2 cy-
tokine production in vitro but also inhibit antigen-driven
CD4  T cell expansion and block allergen-driven lung in-
flammation in vivo in a similar manner as the professional
CD4 CD25  regulatory cells (31, 32). Thus, our findings
provide additional mechanisms for how Treg are generated
and developed. It becomes conceivable for the first time to
design strategies to embellish the limited and/or inadequate
numbers of these suppressor T cells in the periphery, as
needed, for therapeutic intervention in autoimmune dis-
eases, transplantation, cancer, and HIV infection.
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